Roger Jeffs

This profile gathers the share dealings of Roger Jeffs across 3 companies, led by Liquidia Corp, UNITED THERAPEUTICS Corp and Axsome Therapeutics, Inc. We count 62 filings; the first trade dates from 4 January 2016 and the latest from 12 October 2026.

On the open market, the record shows 5 purchases worth €1.4M and 21 sales worth €16.6M. No amount is published for 2 filings, which the totals therefore leave out. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 6 share grants and 22 option exercises. So far in 2026, the count stands at no purchases and 12 sales.

In size, the median ticket on the buying side is €130k. Clusters matter here: 5 out of 5 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 5 purchases with a full 90-day history, the hit rate stands at 40% and the median 90-day move at -9.4%. This is a record of the past, not a forecast.

On 13 October 2026 came the latest disclosure, an option exercise in Liquidia Corp. The last insider purchase was made public on 18 December 2023, 1,035 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.